Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AM...
Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats
About this item
Full title
Author / Creator
Tian, Jingjing , Zhang, Mingjun , Suo, Mengying , Liu, Dian , Wang, Xuyang , Liu, Ming , Pan, Jinyu , Jin, Tao and An, Fengshuang
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Diabetic cardiomyopathy (DCM) is one of the leading causes of heart failure in patients with diabetes mellitus, with limited effective treatments. The cardioprotective effects of sodium‐glucose cotransporter 2(SGLT2) inhibitors have been supported by amounts of clinical trials, which largely fills the gap. However, the underlying mechanism still ne...
Alternative Titles
Full title
Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8358881
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8358881
Other Identifiers
ISSN
1582-1838
E-ISSN
1582-4934
DOI
10.1111/jcmm.16601
